Incidence of intraabdominal infection in a consecutive series of 40 enteric-drained pancreas transplants with FK506 and MMF immunosuppression

Transpl Int. 2000;13 Suppl 1:S195-8. doi: 10.1007/s001470050324.

Abstract

Although the introduction of FK506 and MMF has markedly improved patient and graft outcome after pancreas transplantation, this procedure is still associated with a high surgical complication rate. The aim of the following study was to retrospectively analyze a series of 40 consecutive pancreas transplants with enteric drainage with regard to intraabdominal infection (IAI). Between March 1997 and December 1998 a total of 40 whole pancreas transplants were performed. Prophylactic immunosuppression consisted of an intraoperative single shot ATG (Thymoglobulin), FK506, MMF, and prednisone. The mean observation period was 14.6 (5-26) months. Overall incidence of IAI was 27.5% (n = 11) leading to pancreatectomy in 5 patients (12.5%). In the remaining 6 patients the graft could be rescued by necrosectomy and radical drainage of the abscess (5 patients) or percutaneous drainage (1 patient). Pancreatectomy or local infection did not alter kidney graft function in the 11 patients with simultaneous pancreas kidney transplantation. In 10 patients no evidence for leakage at the site of enteric anastomosis was present, one duodenal leak occurred due to ischemia. IAI in the early postoperative period was the predominat risk factor for graft loss. An early and invasive diagnostic approach is recommended to maximize the chance of graft rescue.

MeSH terms

  • Adult
  • Antilymphocyte Serum / therapeutic use
  • Female
  • Graft Survival*
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Infections / epidemiology*
  • Intestines / surgery
  • Male
  • Middle Aged
  • Mycophenolic Acid / analogs & derivatives*
  • Mycophenolic Acid / therapeutic use
  • Pancreas Transplantation / methods*
  • Pancreas Transplantation / mortality
  • Pancreas Transplantation / physiology
  • Pancreatectomy
  • Postoperative Complications / epidemiology*
  • Retrospective Studies
  • Survival Rate
  • Tacrolimus / therapeutic use*
  • Time Factors

Substances

  • Antilymphocyte Serum
  • Immunosuppressive Agents
  • Mycophenolic Acid
  • Tacrolimus